T1	Intervention 45 92	children with pervasive developmental disorders
T2	Intervention 265 508	Twenty-four children (aged 5-17 years) with pervasive developmental disorders and co-morbid disruptive behavior who responded favorably to open-label treatment with risperidone as part of a previously described controlled discontinuation study
